For much of her early career, Abbie Youkilis, MD focused on changing healthcare from the outside in. Having begun as a pre-med student at Duke, she pivoted into public policy, earning a master’s degree from Harvard and working in Washington on health policy and aging issues. But over time, she found herself drawn back to … Read more
During this year’s World Vaccine Congress, Velocity Clinical Research will host an exclusive “Dine and Discuss” dinner bringing together a select group of senior leaders from across the vaccine and clinical research ecosystem for an off-the-record conversation with vaccine policy and law expert Richard H. Hughes IV. The event forms part of an ongoing series … Read more
There is a logic to the way William Cromwell, MD speaks about cardiometabolic risk — if this, then that. But you never feel as though it would come at the expense of the person sitting opposite him. Over the past 35 years of specialty practice, research, teaching, and publishing, his emphasis has remained the same. … Read more
By Evelyne Newton, Business Development Europe at Velocity Clinical Research Next week I will join industry leaders to explore one of the most pressing questions facing sites across Europe: how can clinical trial sites diversify therapeutic areas sustainably without compromising quality? In a competitive and fast-moving environment, diversification is often framed as a necessary growth … Read more
By Andrew Reina, Chief Revenue Officer Clinical research is at an inflection point. Sponsors and CROs are being asked to deliver trials that start faster, enrol more predictably, and generate data that stands up to increasing regulatory and commercial scrutiny. In that environment, long-standing approaches to site selection, which are often shaped by reputation, relationships, … Read more
Over the course of his career, Matthew Wenker, MD, has moved from hospital wards to Phase I units and, eventually, to leading research across three Velocity sites in Cincinnati. Along the way, he has been Principal Investigator (PI) or sub-investigator on close to 500 studies. What stands out in the way he talks about that … Read more
Across multiple Phase 3 trials, Eli Lilly and Company’s once-weekly insulin efsitora alfa matched daily basal insulin in A1C reduction and demonstrated a similar safety profile. “The novel fixed-dose regimen … has the potential to facilitate and simplify insulin therapy, reducing the hesitation often associated with starting insulin to treat type 2 diabetes,” said Julio … Read more
Congratulations to the Structure Therapeutics team for announcing positive topline data from its ACCESS clinical program for aleniglipron, an oral GLP-1 receptor agonist. Julio Rosenstock, MD, Chair of the ACCESS program Steering Committee and Senior Scientific Advisor at Velocity, is quoted in the press release: “The weight-lowering data from these ACCESS studies, without any evidence … Read more
Henrik Watz, MD, PhD, is the chief investigator and author of trial results for EpiEndo’s clinical trial of glasmacinal (EP395). Results indicated that glasmacinal reduced neutrophilic inflammation in COPD patients without any detectable impact on the lung microbiome, supporting preclinical findings of reduced antimicrobial resistance potential. Dr. Watz in the accompanying press release: “The data … Read more
When you first meet Fritz Raiser, DO, you could be forgiven for thinking he was on holiday. There’s a quiet ease about him, a calm confidence that feels almost out of place for someone who spends half his week in a busy emergency room and his days leading clinical trials. Warm and approachable, Dr. Raiser … Read more